Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects (Salmon-Basel)

Prof. Dominique de Quervain, MD

Status and phase

Completed

Phase 2

Conditions

Memory Functions

Treatments

Drug: Salbutamol

Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01957293

2013DR2134

Details and patient eligibility

About

Aim is to investigate the effect of beta2 adrenergic stimulant salbutamol on emotional and cognitive functions in healthy humans.

Enrollment

40 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy, male and female, aged between 18 and 40, BMI be-tween 19 and 27 kg/m2, normotensive (BP between 90/60 mmHg and 140/90 mmHg), native or fluent German-speaking, caucasian (European ancestry), able and willing to give written informed consent and comply with the requirements of the study protocol, willing to donate saliva sample for DNA-analysis -

Exclusion criteria

Acute or chronic psychiatric or somatic disorder, tachycardia at rest (> 100 bpm), known hypersensitivity to salbutamol, pathological ECG, pregnancy, breast-feeding, long-term medication within last 3 months (oral contraceptives are disregarded) smoking (>3 cigarettes per day), concurrent participation in another study, participation in one of our previous studies using the same memory tests, inability to read and understand the participant's information. -